Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.

Dan Romanoff, CPA | 08 May 2026

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.

Seth Goldstein, CFA | 08 May 2026

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Jacob Robbins | 08 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,980.50	31.60	-0.35%
CAC 40	8,112.57	89.51	-1.09%
DAX 40	24,338.63	324.98	-1.32%
Dow JONES (US)	49,609.16	12.19	0.02%
FTSE 100	10,233.07	43.88	-0.43%
HKSE	26,393.71	232.57	-0.87%
NASDAQ	26,247.08	440.88	1.71%
Nikkei 225	62,713.65	120.19	-0.19%
NZX 50 Index	13,175.13	95.48	-0.72%
S&P 500	7,398.93	61.82	0.84%
S&P/ASX 200	8,744.40	36.40	-0.41%
SSE Composite Index	4,179.95	0.14	-0.00%